Dorothy Hatsukami



I am an adult psychologist and my areas of research expertise include nicotine addiction and its treatment, including testing medications such as a nicotine vaccine and combination medications, in smokers at the Department of Psychiatry & Behavioral Sciences. I received a BA in Psychology from the University of California, Berkeley. I received a PhD in Clinical Psychology at the University of Minnesota and completed my internship at the University of Washington . 

I am the Forster Family Chair in Cancer Prevention at the Masonic Cancer Center of the University of Minnesota and Professor of Psychiatry and Behavioral Sciences. I am the Associate Director of Cancer Prevention and Control at the University of Minnesota Masonic Cancer Center, Director of the Tobacco Research Programs and Deputy Director of the Global Institute for Research on Cancer Prevention. 

Currently, I am PI/Co-PI of a large NIH-funded cooperative agreement and a program project grant that involves assessing the toxicity, appeal and addictiveness of various tobacco products, with the goal of reducing tobacco-caused harm and addiction. I have served on numerous scientific advisory boards for the U.S. government including the 1) Food and Drug Administration, Tobacco Product Scientific Advisory Committee, 2) National Advisory Council on Drug Abuse, 3) Interagency Committee on Smoking and Health, 4) Substance Abuse and Mental Health Services Administration, 5) Scientific Board of Counselors for the National Institutes on Drug Abuse, and 6) the Drug Control Research, Data and Evaluation Committee of the Office on National Drug Control Policy.  I am currently a member of the World Health Organization Study Group on Tobacco Product Regulation and the National Cancer Institute, Board of Scientific Advisors.  


  • Tobacco Addiction
  • Tobacco Regulatory Science
  • Cancer Prevention

Administrative Assistant

(for academic support only)
Tracy Brown

In the Media

Research Summary

Dr. Hatsukami's areas of research expertise are nicotine addiction and its treatment in smokers, including testing medications such as a nicotine vaccine and combination medications.

Clinical Summary

Dr. Hatsukami's clinical interests involve tobacco cessation.


PhD, University of Minnesota
Major: Clinical Psychology Training Program
BA, University of California - Berkeley
Major: Psychology

Fellowships, Residencies, and Visiting Engagements

University of Washington - Seattle, Psychiatry and Behavioral Sciences

Honors and Recognition

ResearHERS, Women Fighting Cancer, Legacy Award, American Cancer Society
Academies for Excellence in Team Science
Wall of Scholarship Award
Dean's Distinguished Research Lectureship Award
Med-Associates, Brady Shuster Award, American Psychological Association, Division 28

Professional Memberships

Academies for Excellence in Health Research Lifetime Membership
Selected Publications

Selected Publications

Cassidy RN, Tidey JW, Jackson KM, Cioe PA, Murphy SE, Krishnan-Sarin S, Hatsukami D, Colby SM., 2023. The Impact of Reducing Nicotine Content on Adolescent Cigarette Smoking and Nicotine Exposure: Results From a Randomized Controlled Trial. Nicotine Tob Res, 25 (5): 918-927.
doi: PubMed ID: 36482794.
Meier E, Rubin N, Dermody SS, Tessier KM, Hecht SS, Murphy S, Jensen J, Donny EC, al'Absi M, Drobes D, Koopmeiners J, Denlinger-Apte R, Tidey JW, Vandrey R, Thorne C, Hatsukami D., 2023. Immediate Switching to Reduced Nicotine Cigarettes in a U.S.-Based Sample: The Impact on Cannabis Use and Related Variables at 20 Weeks. Nicotine Tob Res, 25 (5): 867-874.
doi: PubMed ID: 36198101.
Edwards KC, Ozga JE, Reyes-Guzman C, Smith D, Hatsukami D, Hart JL, Jackson A, Goniewicz M, Stanton CA., 2023. Associations between biomarkers of nicotine/tobacco exposure and respiratory symptoms among adults who exclusively smoke cigarettes in the U.S.: Findings from the PATH Study Waves 1-4 (2013-2017). Addict Behav Rep, 17:100487
Denlinger-Apte RL, Cassidy RN, Donny EC, Godin J, Hatsukami DK, Strahley AE, Wiseman KD, Colby SM, Tidey JW., 2023. Qualitative reactions to a low nicotine product standard for cigarettes from adolescents and young adults living in the United States who smoke.. Prev Med Rep, 32 102163.
Katz SJ, Petersen A, Liu H, Cohen E, Hatsukami D., 2023. Vaping Flavors and Flavor Representation: A Test of Youth Risk Perceptions, Novelty Perceptions, and Susceptibility. Nicotine Tob Res, 25 (3): 590-595.
doi: PubMed ID: 35931419.
Diaz D, Luo X, Hatsukami DK, Donny EC, O'Connor RJ., 2022. Cigarette filter ventilation, smoking topography, and subjective effects: A mediational analysis. Drug and alcohol dependence. Drug Alcohol Depend, 241 109683.
Paulin, L.M., Halenar, M.J., Edwards, K.C. Hatsukami, D. et al. , 2022. Association of tobacco product use with chronic obstructive pulmonary disease (COPD) prevalence and incidence in Waves 1 through 5 (2013–2019) of the Population Assessment of Tobacco and Health (PATH) Study. Respiratory Research, 23 (273):
Mowls Carroll D, Hatsukami D, Denlinger-Apte R., 2022. Prioritize health equity when implementing a nicotine product standard. Nicotine & Tobacco Research, 25 (1): 173-174.
doi: PubMed ID: 35867991.
Klemperer EM, Luo X, Jensen J, al'Absi M, Cinciripini PM, Robinson JD, Drobes DJ, McClernon J, Strasser AA, Strayer LG, Vandrey R, Benowitz NL, Donny EC, Hatsukami DK., 2022. Smoking abstinence and cessation-related outcomes one month after an immediate versus gradual reduction in nicotine content of cigarettes. Prev Med, 165 (Pt B): 107175.
Chen M, Carmella SG, Lindgren BR, Luo X, Ikuemonisan J, Niesen B, Thomson NM, Murphy SE, Hatsukami DK, Hecht SS., 2022. Increased levels of the acrolein metabolite 3-hydroxypropyl mercapturic acid in the urine of e-cigarette users. Chem Res Toxicol, 36 (4): 583-588.



Department of Psychiatry & Behavioral Sciences, F282/2A West Building, 2450 Riverside Avenue South, Minneapolis, MN 55454